Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy
Anti-Cancer Drugs,  Clinical Article

Zhao HY et al. – The results provide evidence that the thymidine phosphorylase (TP) expression may be a prognostic factor in breast cancer patients treated with capecitabine–based first–line chemotherapy, and βIII–tubulin can be used to predict the outcome of capecitabine in combination with taxanes as first–line chemotherapy. Therefore, these potential biomarkers should be further evaluated.

  • The authors evaluated the clinicopathological/prognostic significance of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), class III β-tubulin (βIII-tubulin), and stathmin-1 or oncoprotein-18 (STMN1).
  • Formalin-fixed, paraffin-embedded tumor specimens from 42 patients were used for analysis of TS, DPD, TP, βIII–tubulin, and STMN1 expression with a real-time reverse transcription-PCR technique.
  • Patients were classified into the high-expression and low-expression groups according to the median value of the expression level of each biomarker.
  • There was a significantly longer time to progression (TTP) in the high-TP group (P=0.018).

  • The multivariate analysis revealed that the TP expression (hazard ratio for the low-TP group vs. the high-TP group, 2.873; 95% confidence interval, 1.143–7.223; P=0.025) is independent of prognostic factors for TTP.
  • In the subgroup of patients treated with capecitabine plus taxanes as first-line chemotherapy, TTP was significantly longer in the low-βIII-tubulin group (P=0.047).
  • The gene expression of TS, DPD, and STMN1 failed to have any significant impact on the outcome.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More